Next Century Growth Investors LLC Sells 176 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Next Century Growth Investors LLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.6% in the second quarter, HoldingsChannel reports. The firm owned 4,704 shares of the biopharmaceutical company’s stock after selling 176 shares during the period. Next Century Growth Investors LLC’s holdings in Regeneron Pharmaceuticals were worth $2,627,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of REGN. Zions Bancorporation N.A. grew its position in shares of Regeneron Pharmaceuticals by 66.7% during the 1st quarter. Zions Bancorporation N.A. now owns 55 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 22 shares during the period. Gleason Group Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $31,000. Arkadios Wealth Advisors grew its position in shares of Regeneron Pharmaceuticals by 96.6% during the 2nd quarter. Arkadios Wealth Advisors now owns 57 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 28 shares during the period. Sandy Spring Bank grew its position in shares of Regeneron Pharmaceuticals by 416.7% during the 2nd quarter. Sandy Spring Bank now owns 62 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 50 shares during the period. Finally, Sierra Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $36,000. 82.31% of the stock is owned by institutional investors and hedge funds.

NASDAQ REGN traded up $8.95 during trading hours on Thursday, reaching $556.07. The company had a trading volume of 3,969 shares, compared to its average volume of 859,127. The stock has a 50-day moving average of $628.24 and a 200 day moving average of $561.38. Regeneron Pharmaceuticals, Inc. has a 1-year low of $441.00 and a 1-year high of $686.62. The company has a current ratio of 3.57, a quick ratio of 3.04 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $59.47 billion, a P/E ratio of 9.82, a price-to-earnings-growth ratio of 0.77 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 5th. The biopharmaceutical company reported $25.80 EPS for the quarter, beating the Zacks’ consensus estimate of $8.81 by $16.99. Regeneron Pharmaceuticals had a net margin of 50.11% and a return on equity of 50.43%. The company had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $3.90 billion. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 51.91 EPS for the current year.

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Friday, October 1st. The shares were sold at an average price of $569.49, for a total value of $56,949.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction dated Friday, October 1st. The shares were sold at an average price of $576.75, for a total transaction of $576,750.00. The disclosure for this sale can be found here. Insiders have sold 304,558 shares of company stock worth $194,944,747 over the last quarter. Insiders own 11.84% of the company’s stock.

REGN has been the topic of several research analyst reports. Morgan Stanley decreased their price target on shares of Regeneron Pharmaceuticals from $606.00 to $571.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Barclays upped their price target on shares of Regeneron Pharmaceuticals from $675.00 to $705.00 and gave the company an “overweight” rating in a report on Friday, August 6th. Piper Sandler upped their price target on shares of Regeneron Pharmaceuticals from $675.00 to $690.00 and gave the company an “overweight” rating in a report on Wednesday, September 15th. SVB Leerink upped their price target on shares of Regeneron Pharmaceuticals from $641.00 to $725.00 and gave the company an “outperform” rating in a report on Friday, August 6th. Finally, BMO Capital Markets upped their price target on shares of Regeneron Pharmaceuticals from $669.00 to $706.00 and gave the company an “outperform” rating in a report on Tuesday, September 21st. Three investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $691.76.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.

Recommended Story: Cash Asset Ratio

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.